Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Oncology

Life After Treatment: Surveillance and Your Long-Term Health

At a Glance

After curative treatment for hepatocellular carcinoma (HCC), regular surveillance with MRI or CT scans and AFP blood tests every 3 to 6 months is crucial. This proactive monitoring helps catch early recurrence and protects your long-term liver health.

Return to Home

Finishing a curative treatment like surgery or a transplant is a major milestone, but it also marks the beginning of a new phase: surveillance [1][2]. Because HCC has a high chance of returning, regular monitoring is the most important tool you have to protect your health and catch any issues early [1][3].

The Surveillance Roadmap

For the first few years after treatment, your doctors will keep a very close eye on your liver. While every hospital is slightly different, a typical schedule includes:

  • Imaging (Scans): You will likely have an MRI or CT scan every 3 to 6 months for the first two years [1]. MRI is often preferred because it is better at spotting very small new tumors (less than 30 mm) [4][5].
  • Bloodwork: You will have regular tests for AFP (Alpha-fetoprotein). While AFP isn’t perfect, it acts as a “smoke detector” that works alongside your scans to alert doctors to potential changes [6][7].

Understanding Recurrence: The “Two-Year” Window

Doctors generally divide recurrence into two categories based on when it happens:

  1. Early Recurrence (Less than 2 years): This usually happens because original cancer cells were hidden or aggressive [8][9]. Factors like microvascular invasion (MVI)—where tiny cancer cells are found in the small blood vessels near the tumor—increase this risk [10][11].
  2. Late Recurrence (More than 2 years): This is often not the “old” cancer coming back, but rather a “de novo” (brand new) tumor forming because the underlying liver is still scarred or diseased [8][11].

Recurrence Rates by Treatment

The risk of the cancer returning depends heavily on which treatment you received:

  • Liver Transplantation: This has the lowest recurrence rate because the entire “diseased environment” (the liver) was replaced [12].
  • Surgical Resection: This has a higher risk than a transplant because the original, potentially scarred liver remains [13][14]. However, it still offers a high chance of long-term survival [15].
  • Ablation: This generally has a higher recurrence rate than surgery, especially for larger tumors, though it is much easier on the body [13][16].

Managing “Scanxiety”

It is completely normal to feel intense dread or anxiety in the days leading up to a scan—a phenomenon often called scanxiety [17][18]. Many patients describe this feeling as a “Sword of Damocles” hanging over them [19][20].

Research suggests several ways to manage this distress:

  • Ask for Results Early: Ask your doctor the fastest way to get results—sometimes portals release them before the doctor calls [19].
  • Mindfulness and Support: Non-drug treatments like mindfulness, deep breathing exercises, and nurse-led support groups can significantly reduce anxiety during the waiting period [21][22][23].
  • Knowledge is Power: Your doctor may use nomograms (risk-calculators) that look at your tumor’s size, AFP, and MVI status to give you a more accurate, personalized picture of your risk, which can sometimes provide more peace of mind than “generic” statistics [24][25].

By staying committed to your surveillance schedule, you ensure that if the “two-disease” nature of HCC tries to resurface, you and your team are ready to meet it immediately [1][26].

Common questions in this guide

How often will I need scans after HCC treatment?
For the first few years after treatment, you will typically need an MRI or CT scan every 3 to 6 months. MRI is often preferred because it is better at detecting very small new tumors before they cause symptoms.
What is the difference between early and late liver cancer recurrence?
Early recurrence happens within the first two years, usually from original cancer cells that were hidden. Late recurrence occurs after two years and is often a brand new tumor forming due to underlying liver scarring or disease.
Does microvascular invasion (MVI) mean my liver cancer will come back?
Microvascular invasion means tiny cancer cells were found in small blood vessels near the original tumor. While it does increase the risk of early recurrence, regular monitoring will help catch any changes quickly.
What does it mean if my AFP levels rise after liver cancer treatment?
A rising AFP level acts as an early warning sign, but it does not definitively mean the cancer has returned. Your doctor will use your AFP results alongside your MRI or CT scans to determine the appropriate next steps.
How can I manage anxiety before my liver cancer scans?
It is completely normal to experience intense dread or 'scanxiety' before follow-up testing. You can manage this distress by practicing mindfulness, joining support groups, and asking your doctor the fastest way to get your scan results.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my personalized surveillance schedule for the next two years, and will we be using MRI or CT scans?
  2. 2.Did my pathology report show 'microvascular invasion' (MVI) or other high-risk factors for recurrence?
  3. 3.If my AFP levels begin to rise but the scans look clear, what are our next steps?
  4. 4.How quickly will my results be available in the patient portal, and who should I contact if I have high anxiety while waiting?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (26)
  1. 1

    Circulating exosomal miR-92b: Its role for cancer immunoediting and clinical value for prediction of posttransplant hepatocellular carcinoma recurrence.

    Nakano T, Chen IH, Wang CC, et al.

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2019; (19(12)):3250-3262 doi:10.1111/ajt.15490.

    PMID: 31162867
  2. 2

    Radiomic Features at Contrast-enhanced CT Predict Recurrence in Early Stage Hepatocellular Carcinoma: A Multi-Institutional Study.

    Ji GW, Zhu FP, Xu Q, et al.

    Radiology 2020; (294(3)):568-579 doi:10.1148/radiol.2020191470.

    PMID: 31934830
  3. 3

    Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.

    Qin S, Chen M, Cheng AL, et al.

    Lancet (London, England) 2023; (402(10415)):1835-1847 doi:10.1016/S0140-6736(23)01796-8.

    PMID: 37871608
  4. 4

    The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced ultrasound in detecting hepatocellular carcinoma: A meta-analysis.

    Wang J, Ye X, Li J, He S

    Medicine 2021; (100(6)):e24602 doi:10.1097/MD.0000000000024602.

    PMID: 33578564
  5. 5

    Role of imaging in management of hepatocellular carcinoma: surveillance, diagnosis, and treatment response.

    Osho A, Rich NE, Singal AG

    Hepatoma research 2020; (6()) doi:10.20517/2394-5079.2020.42.

    PMID: 32944652
  6. 6

    Does alpha-fetoprotein contribute to the mortality and morbidity of human hepatocellular carcinoma? A commentary.

    Mizejewski GJ

    Journal of hepatocellular carcinoma 2016; (3()):37-40 doi:10.2147/JHC.S114198.

    PMID: 27703963
  7. 7

    Alpha-fetoprotein accelerates the progression of hepatocellular carcinoma by promoting Bcl-2 gene expression through an RA-RAR signalling pathway.

    Zhang C, Zhang J, Wang J, et al.

    Journal of cellular and molecular medicine 2020; (24(23)):13804-13812 doi:10.1111/jcmm.15962.

    PMID: 33090723
  8. 8

    Association of Preoperative Antiviral Treatment With Incidences of Microvascular Invasion and Early Tumor Recurrence in Hepatitis B Virus-Related Hepatocellular Carcinoma.

    Li Z, Lei Z, Xia Y, et al.

    JAMA surgery 2018; (153(10)):e182721 doi:10.1001/jamasurg.2018.2721.

    PMID: 30073257
  9. 9

    Microvascular invasion risk scores affect the estimation of early recurrence after resection in patients with hepatocellular carcinoma: a retrospective study.

    Wang S, Zheng W, Zhang Z, et al.

    BMC medical imaging 2022; (22(1)):204 doi:10.1186/s12880-022-00940-0.

    PMID: 36419016
  10. 10

    Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial.

    Wang K, Xiang YJ, Yu HM, et al.

    Nature medicine 2024; (30(3)):708-715 doi:10.1038/s41591-023-02786-7.

    PMID: 38242982
  11. 11

    Grading severity of MVI impacts long-term outcomes after laparoscopic liver resection for early-stage hepatocellular carcinoma: A multicenter study.

    Yang S, Ni H, Zhang A, et al.

    American journal of surgery 2024; (238()):115988 doi:10.1016/j.amjsurg.2024.115988.

    PMID: 39342882
  12. 12

    Utility of Inflammatory Markers in Predicting Hepatocellular Carcinoma Survival after Liver Transplantation.

    Ismael MN, Forde J, Milla E, et al.

    BioMed research international 2019; (2019()):7284040 doi:10.1155/2019/7284040.

    PMID: 31737675
  13. 13

    Comparison of 2 curative treatment options for very early hepatocellular carcinoma: Efficacy, recurrence pattern, and retreatment.

    Kim TH, Chang JM, Um SH, et al.

    Medicine 2019; (98(26)):e16279 doi:10.1097/MD.0000000000016279.

    PMID: 31261600
  14. 14

    Oncological Outcomes of Hepatic Resection vs Transplantation for Localized Hepatocellular Carcinoma.

    Akcam AT, Saritas AG, Ulku A, Rencuzogullari A

    Transplantation proceedings 2019; (51(4)):1147-1152 doi:10.1016/j.transproceed.2019.01.093.

    PMID: 31101189
  15. 15

    Surgical resection versus radiofrequency ablation for Barcelona Clinic Liver Cancer very early stage hepatocellular carcinoma: long-term results of a single-center study.

    Hsiao CY, Hu RH, Ho CM, et al.

    American journal of surgery 2020; (220(4)):958-964 doi:10.1016/j.amjsurg.2020.03.017.

    PMID: 32247523
  16. 16

    Comparison of Surgical Resection and Radiofrequency Ablation in Elderly Patients with Hepatocellular Carcinoma.

    Kim JI, Lee J, Choi GH, et al.

    Digestive diseases and sciences 2024; (69(3)):1055-1067 doi:10.1007/s10620-023-08245-0.

    PMID: 38300416
  17. 17

    Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions.

    Derry-Vick HM, Heathcote LC, Glesby N, et al.

    Cancers 2023; (15(5)) doi:10.3390/cancers15051381.

    PMID: 36900174
  18. 18

    The patient perspective in the era of personalized medicine: What about scanxiety?

    Custers JAE, Davis L, Messiou C, et al.

    Cancer medicine 2021; (10(9)):2943-2945 doi:10.1002/cam4.3889.

    PMID: 33837668
  19. 19

    Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

    Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

    European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

    PMID: 38311702
  20. 20

    Exploring the lived experiences of women with metastatic breast cancer and their HRQoL questionnaire preferences: a qualitative study.

    Tolstrup LK, Vogsen M, Hildebrandt MG, et al.

    Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2026; (35(2)):32.

    PMID: 41511649
  21. 21

    Scan-Associated Distress in People Affected by Cancer: A Qualitative Systematic Review.

    Hussain M, Chau S, Turner M, Paterson C

    Seminars in oncology nursing 2023; (39(5)):151502 doi:10.1016/j.soncn.2023.151502.

    PMID: 37735038
  22. 22

    Pre-procedural virtual reality education reduces anxiety in patients undergoing atrial septal closure - Results from a randomized trial.

    Oudkerk Pool MD, Hooglugt JQ, Kraaijeveld AJ, et al.

    International journal of cardiology. Congenital heart disease 2022; (7()):100332 doi:10.1016/j.ijcchd.2022.100332.

    PMID: 39712270
  23. 23

    Effectiveness of a Nurse-Led Intervention on Pre-procedural Anxiety Among Patients Undergoing Endoscopy: A Quasi-experimental Trial.

    Chaudhary V, Sharma S, Kumar A, et al.

    Cureus 2025; (17(9)):e93166 doi:10.7759/cureus.93166.

    PMID: 41146808
  24. 24

    How to Predict Recurrence After Resection of Hepatocellular Carcinoma.

    Petruch N, Bolm L, Nebbia M, et al.

    Anticancer research 2025; (45(1)):189-199 doi:10.21873/anticanres.17404.

    PMID: 39740812
  25. 25

    Pre- to postoperative alpha-fetoprotein ratio-based nomogram to predict tumor recurrence in patients with hepatocellular carcinoma.

    Yang C, Wang H, Liu J, et al.

    Frontiers in oncology 2023; (13()):1134933 doi:10.3389/fonc.2023.1134933.

    PMID: 37124520
  26. 26

    Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma.

    Pecorelli A, Lenzi B, Gramenzi A, et al.

    Liver international : official journal of the International Association for the Study of the Liver 2017; (37(3)):423-433 doi:10.1111/liv.13242.

    PMID: 27566596

This page provides general information about hepatocellular carcinoma (HCC) surveillance and recurrence. It is for informational purposes only and does not replace professional medical advice. Always consult your oncology team for your specific follow-up plan.

Get notified when new evidence is published on Hepatocellular carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.